Immunomic Therapeutics Reports the First Patient Dosing of ITI-1001 in P-I Clinical Trial for the Treatment of Glioblastoma Multiforme
Shots:
- The first patient has been dosed in the P-I trial of ITI-1001 in patients with Glioblastoma Multiforme. The study is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts & is being led by Dr. David Reardon, Clinical Director, Center for Neuro-Oncology
- The trial is designed to evaluate the safety, tolerability, immunogenicity & preliminary efficacy of ITI-1001 (8mg) in patients having unmethylated MGMT promoter mutations. The results are expected in Q2’25
- ITI-1001, a plasmid DNA vaccine therapy that uses Immunomic’s UNITE platform to treat patients with newly diagnosed GBM. The therapy targets pp65, IE-1, and gB viral Ag of Cytomegalovirus (CMV) which are expressed in GBM but not in normal brain cells
Ref: PRNewswire | Image: Immunomic Therapeutics
Related News:- Telix Reports the First Patient Dosing of TLX101 in P-I Study (IPAX-2) for Newly Diagnosed Glioblastoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
